Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1921438 | 0.83 | LTA4H (0.56) | RAB9ANPC1LTA4HMAPK14SMN1; SMN2 | |
| SCHEMBL9686533 | 0.83 | NPC1 (0.57) | RAB9ANPC1LTA4HMAPK14SMN1; SMN2 | |
| SCHEMBL27674368 | 0.82 | NCF1 (0.54) | RAB9ANPC1LTA4HMAPK14SMN1; SMN2 | |
| SCHEMBL7222828 | 0.81 | CYP1A2 (0.59) | RAB9ANPC1LTA4HMAPK14SMN1; SMN2 | |
| SCHEMBL9847559 | 0.81 | CYP11B1 (0.45) | RAB9ANPC1SMN1; SMN2MAPTKDM1A | |
| SCHEMBL10644141 | 0.80 | CYP1A2 (0.53) | RAB9ANPC1LTA4HMAPK14SMN1; SMN2 | |
| SCHEMBL7843486 | 0.79 | LTA4H (0.56) | RAB9ANPC1LTA4HMAPK14SMN1; SMN2 | |
| SCHEMBL11084194 | 0.79 | LTA4H (0.56) | RAB9ANPC1LTA4HMAPK14SMN1; SMN2 | |
| SCHEMBL10644419 | 0.79 | MCHR1 (0.54) | RAB9ANPC1LTA4HMAPK14SMN1; SMN2 | |
| SCHEMBL21730396 | 0.79 | KDM1A (0.40) | RAB9ANPC1SMN1; SMN2MAPTKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022148422-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2022-07-14 | — | — | WO | disclosed |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| EP-2139888-A2 | IMIDAZOÝ1,2-A¨PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008121687-A2 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| WO-2007095588-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| US-5459132-A | Inhibition of cell proliferation, analgesic, hypotensive | LABORATOIRES UPSA (FR) | 1995-10-17 | — | — | US | disclosed |
| WO-1995018817-A1 | NOVEL ADENOSINE DERIVATIVES, PREPARATION METHODS THEREFOR, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LABORATOIRES UPSA (FR) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | PIK3CA, PIK3CD, PIK3CB | RAB9A 1046/4885NPC1 1650/4885LTA4H 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.